24-Dec-2025
Business Wire (Fri, 12-Dec 4:56 PM ET)
Innoviva’s Zoliflodacin Phase 3 Results Signal a Turning Point in Gonorrhea Treatment
Market Chameleon (Fri, 12-Dec 2:31 AM ET)
Business Wire (Thu, 11-Dec 6:35 PM ET)
Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference
Business Wire (Tue, 25-Nov 7:00 AM ET)
Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress
Business Wire (Wed, 5-Nov 4:05 PM ET)
Antheia Appoints Eric d'Esparbes as Chief Financial Officer
PRNewswire (Tue, 21-Oct 8:00 AM ET)
Business Wire (Mon, 20-Oct 8:00 AM ET)
Business Wire (Tue, 7-Oct 8:00 AM ET)
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
Innoviva trades on the NASDAQ stock market under the symbol INVA.
As of December 24, 2025, INVA stock price climbed to $19.77 with 358,421 million shares trading.
INVA has a beta of 0.13, meaning it tends to be less sensitive to market movements. INVA has a correlation of 0.01 to the broad based SPY ETF.
INVA has a market cap of $1.48 billion. This is considered a Small Cap stock.
Last quarter Innoviva reported $108 million in Revenue and $1.08 earnings per share. This beat revenue expectation by $15 million and exceeded earnings estimates by $.66.
In the last 3 years, INVA traded as high as $22.76 and as low as $10.64.
The top ETF exchange traded funds that INVA belongs to (by Net Assets): IJR, VTI, AVUV, IWM, VB.
INVA has underperformed the market in the last year with a price return of +11.1% while the SPY ETF gained +17.3%. INVA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +3.5% and -4.5%, respectively, while the SPY returned +4.4% and +1.4%, respectively.
INVA support price is $19.15 and resistance is $19.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INVA shares will trade within this expected range on the day.